What is the correct dosing schedule for Vivitrol (extended-release naltrexone) in a patient who has been opioid‑free for 7–10 days with normal or mildly elevated liver enzymes, including the oral test‑dose protocol and follow‑up monitoring?

How to Dose Vivitrol

Administer Vivitrol 380 mg as a deep intramuscular gluteal injection every 4 weeks (monthly), alternating buttocks with each injection, and ensure the patient has been opioid-free for a minimum of 7-10 days before the first dose. 1

Pre-Treatment Requirements

Opioid-Free Period

• Mandatory 7-10 day opioid-free period before initiating Vivitrol to avoid precipitating severe opioid withdrawal that may require hospitalization 1
• Verify opioid-free status through:
  • Urine drug screen (must be negative for opioids)
  • Naloxone challenge test if uncertain 1
  • Patient self-report of last opioid use

Baseline Monitoring

• Obtain baseline liver function tests before starting treatment 2
• Repeat liver enzymes every 3-6 months during treatment, as naltrexone has been associated with hepatotoxicity at supratherapeutic doses 2

Dosing Protocol

Standard Dose

• 380 mg intramuscular injection 1
• Route: Deep intramuscular gluteal injection ONLY—never subcutaneous, intravenous, or any other route 1
• Frequency: Every 4 weeks (monthly) 1
• Technique: Alternate buttocks with each subsequent injection 1

Administration Details

• Must be prepared and administered by a healthcare provider—this is not for patient self-administration 1
• Use only the customized needles provided in the carton (1.5-inch or 2-inch) 1
• Assess body habitus before each injection:
  • Larger patients with more subcutaneous tissue: use 2-inch needle
  • Very lean patients: 1.5-inch needle may be appropriate to avoid periosteal contact
  • Average body habitus: either needle acceptable 1
• Properly mixed suspension should be milky white, free of clumps, and move freely down the vial wall 1

Missed Doses

• If a patient misses a dose, administer the next injection as soon as possible 1
• Critical safety consideration: Patients are at increased risk of fatal opioid overdose after missing doses, at the end of dosing intervals, or after discontinuing treatment due to reduced opioid tolerance 1

Opioid Overdose Prevention Strategy

At each injection visit, strongly consider recommending or prescribing an opioid reversal agent (naloxone or nalmefene) for emergency treatment of opioid overdose 1. This is particularly important because:

• Patients may relapse after treatment discontinuation
• Opioid tolerance is reduced from baseline during treatment
• Risk is highest near the end of the monthly dosing interval or after missed doses 1

Discuss with patients and caregivers:

• How to obtain reversal agents (prescription, over-the-counter, or community programs)
• Differences in administration routes and pharmacokinetics among available products 1

Alternative Induction Approaches (When Standard Protocol Is Challenging)

While the FDA label recommends the 7-10 day opioid-free period, emerging evidence supports rapid induction protocols that may improve treatment access:

Rapid Protocol Option

Recent research demonstrates a 1-week outpatient rapid induction that achieved 62.7% successful initiation compared to 35.8% with standard protocol 3:

• Day 1: Single dose of buprenorphine 6-8 mg after 12+ hours of opioid abstinence
• Days 2-5: Adjunctive medications (clonidine, clonazepam, antiemetics)
• Days 3-5: Ascending oral naltrexone (starting at 1 mg, up to 24 mg)
• Day 5: Vivitrol injection 1 hour after tolerating oral naltrexone 24 mg 4, 5

Important caveat: This rapid approach requires more intensive medical management and safety monitoring, with higher rates of targeted safety events (5.3% vs 2.1%) and serious adverse events (6.7% vs 1.6%) compared to standard protocol 3. This is not FDA-approved but represents an evidence-based alternative when the standard approach fails.

Contraindications (Absolute)

Do not administer Vivitrol if the patient:

• Is currently receiving opioid analgesics
• Has current physiologic opioid dependence
• Is in acute opioid withdrawal
• Failed naloxone challenge test or has positive urine opioid screen
• Has hypersensitivity to naltrexone or formulation components 1

Critical Safety Warnings

Pain Management Considerations

• Vivitrol blocks all opioid effects—patients cannot receive opioid analgesia while on treatment 2
• In emergencies requiring pain control, use regional analgesia or non-opioid analgesics 1
• Attempts to overcome the opioid blockade with high-dose opioids can lead to fatal overdose 1

Injection Site Reactions

• Monitor for severe injection site reactions that may require surgical intervention 1
• Proper deep intramuscular technique is essential to minimize this risk

Hepatotoxicity

• Discontinue Vivitrol if signs or symptoms of acute hepatitis develop 1
• Regular monitoring (every 3-6 months) is essential 2

Psychiatric Monitoring

• Monitor for development of depression or suicidal thinking throughout treatment 1

Integration with Comprehensive Care

Vivitrol should always be part of a comprehensive management program including psychosocial support 1. The medication alone is insufficient—behavioral therapy focused on medication adherence and relapse prevention is essential for optimal outcomes 5.